Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1

Wing Man Chan¹,³,⁴,†, Ho Tsoi¹,⁴,†, Chi Chung Wu¹,³, Chi Hang Wong⁵, Tat Cheung Cheng¹,³, Hoi Yeung Li⁵, Kwok Fai Lau²,³,⁴, Pang Chui Shaw⁴, Norbert Perrimon⁶ and Ho Yin Edwin Chan¹,²,³,⁴,*

¹Laboratory of Drosophila Research, ²Cell and Molecular Biology Program, ³Molecular Biotechnology Program and ⁴Department of Biochemistry, Faculty of Science, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China, ⁵Division of Molecular and Cell Biology, School of Biological Sciences, College of Science, Nanyang Technological University, 637551 Singapore and ⁶Department of Genetics and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA

Received December 25, 2010; Revised December 25, 2010; Accepted February 2, 2011

Polyglutamine (polyQ) diseases are a group of late-onset, progressive neurodegenerative disorders caused by CAG trinucleotide repeat expansion in the coding region of disease genes. The cell nucleus is an important site of pathology in polyQ diseases, and transcriptional dysregulation is one of the pathologic hallmarks observed. In this study, we showed that exportin-1 (Xpo1) regulates the nucleocytoplasmic distribution of expanded polyQ protein. We found that expanded polyQ protein, but not its unexpanded form, possesses nuclear export activity and interacts with Xpo1. Genetic manipulation of Xpo1 expression levels in transgenic Drosophila models of polyQ disease confirmed the specific nuclear export role of Xpo1 on expanded polyQ protein. Upon Xpo1 knockdown, the expanded polyQ protein was retained in the nucleus. The nuclear disease protein enhanced polyQ toxicity by binding to heat shock protein (hsp) gene promoter and abolished hsp gene induction. Further, we uncovered a developmental decline of Xpo1 protein levels in vivo that contributes to the accumulation of expanded polyQ protein in the nucleus of symptomatic polyQ transgenic mice. Taken together, we first showed that Xpo1 is a nuclear export receptor for expanded polyQ domain, and our findings establish a direct link between protein nuclear export and the progressive nature of polyQ neurodegeneration.

INTRODUCTION

Polyglutamine (polyQ) diseases are a group of neurodegenerative disorders characterized by the pathogenic expansion of existing CAG trinucleotide repeats in the coding region of disease genes, which are translated into expanded polyQ domains in disease proteins (1). Despite the diverse regional vulnerabilities of the nine polyQ diseases identified thus far, they share several salient pathologic features, including progressive neurodegeneration usually striking in midlife, formation of insoluble protein aggregates and transcriptional dysregulation of essential genes in affected neurons (1). The cell nucleus is regarded as a major site of toxicity in different polyQ disease models (2–11). The nucleocytoplasmic localization of cellular proteins is governed by nuclear transport signals, which are short stretches of amino acids on them and recognized by specific transport receptors/adaptors (12). The nuclear transport receptors/adaptors interact with their...
substrates and mediate nuclear transport across the nuclear envelope (13). Previous studies show that polyQ domain expansion not only causes nuclear localization of disease protein (14), but also compromises the function of nuclear transport signals on disease proteins and thus alters their subcellular localization (15,16).

To investigate the nuclear transport property of expanded polyQ domain per se, we initially took advantage of an inducible *Drosophila* cell model to test whether any nuclear transport receptors/adaptors would modulate expanded polyQ protein nuclearcytoplasmic localization. Notably, our knockdown data implied that expanded polyQ domain mediated protein nuclear export through an exportin-1 (Xpo1)-dependent pathway. We then focused on elucidating the nuclear export property of an expanded polyQ domain and its associated modification on polyQ toxicity by Xpo1. We found that an expanded polyQ domain, but not its unexpanded form, carried nuclear export activity and physically interacted with Xpo1. Retention of expanded polyQ protein in the nucleus due to Xpo1 knockdown led to impairment of heat shock protein (hsp) gene induction and therefore enhanced toxicity. This suggests that nuclear export of expanded polyQ protein helps in maintaining the cellular heat shock response during the course of polyQ pathogenesis. We also reported a temporal decline of Xpo1 levels in both wild-type and polyQ transgenic mice. The gradual decrease of Xpo1 protein levels during aging explains, at least in part, the progressive nature of polyQ neurodegeneration. This study first reports an expanded polyQ domain-specific nuclear export pathway, which involves Xpo1 as the export receptor. Identifying the nuclear transport pathways that govern the nuclearcytoplasmic localization of expanded polyQ protein will open up new directions for mechanistic studies of polyQ pathogenesis and therapeutic development.

**RESULTS**

**Nuclear transport receptors/adaptors modulate subcellular localization of polyQ aggregates**

An inducible *Drosophila* neuronal BG2 cell model that stably expressed enhanced green fluorescent protein (EGFP)–polyQ fusion proteins (EGFP–Q27 or EGFP–Q75) was established to study the nuclear transport property of polyQ domain. At 96 h post-induction, the unexpanded EGFP–Q27 was found diffusely localized in both the cytoplasm and nucleus of BG2 cells, whereas expanded EGFP–Q75 formed aggregates in both compartments (Fig. 1A). In order to test whether nuclear transport receptor/adaptor would regulate the nucleocytoplasmic distribution of proteins carrying an expanded polyQ domain, the expression of 19 receptor/adaptor genes in the *Drosophila* genome was knocked down by double-stranded RNA (dsRNA) in BG2 cells (Fig. 1B), and their effects on the subcellular localization of expanded polyQ protein were examined (Table 1). Among all the genes investigated, Xpo1 was the only one whose knockdown caused a significant buildup of EGFP–Q75 in the nucleus. No such effect was observed with the unexpanded EGFP–Q27 control (data not shown), implying the Xpo1 knockdown effect is expanded polyQ specific.

**Expanded polyQ domain mediates protein nuclear export through an Xpo1-dependent pathway**

Exportin-1 is a well-characterized nuclear export receptor (17). Our Xpo1 knockdown data (Table 1) advocated the claim that the expanded polyQ protein is an export substrate of Xpo1. We therefore sought to assess the nuclear export activity of expanded polyQ domain by the well-established Rev(1.4)–EGFP nuclear export assay (18). To do this, different lengths of polyQ domains were tagged to the Rev(1.4)–EGFP reporter protein (Supplementary Material, Fig. S1A). Transfected HEK293 cells were treated with cycloheximide and actinomycin D to stop protein synthesis and nuclear import of the Rev(1.4)–polyQ–EGFP reporter protein, respectively (18). Any green fluorescent protein (GFP) signal detected in the cytoplasm would thus be attributable to the nuclear export activity conferred by the appended polyQ domain. The controls, i.e. Rev(1.4)–EGFP protein carrying either no (Q0) or an unexpanded (Q19) polyQ domain, showed a predominant nuclear localization (Fig. 2A and B), indicating that unexpanded polyQ domain has no detectable nuclear export signal (NES) activity. However, the addition of an expanded polyQ domain (Q78) to Rev(1.4)–EGFP caused a significant cytoplasmic shift of the reporter protein (Fig. 2A and B). This clearly demonstrated that expanded polyQ domain possesses nuclear export activity. To confirm the involvement of Xpo1 in mediating the nuclear export of expanded polyQ domain-containing protein, we treated cells with leptomycin B (LMB), a potent inhibitor of Xpo1-mediated nuclear export (19,20). Upon LMB treatment, we found a noticeable nuclear shift of Rev(1.4)–Q78–EGFP from the cytoplasm (Fig. 2A). Consistent with western blot analysis (Fig. 2A), we observed a significant reduction in the number of cells that displayed cytoplasmic localization of the Rev(1.4)–Q78–EGFP protein after LMB treatment (Fig. 2B). We also observed a similar change in Rev(1.4)–Q78–EGFP subcellular localization when Xpo1 expression was knocked down by small interfering RNA (siRNA) in HEK293 cells (Fig. 2C and D; Supplementary Material, Fig. S1B). Altogether, our data clearly demonstrated that expanded polyQ domain is a functional NES and Xpo1 is the receptor that mediates protein nuclear export of expanded polyQ protein.

To gain further insight into the involvement of Xpo1 in expanded polyQ domain-mediated nuclear export, we tested whether an expanded polyQ domain would physically interact with Xpo1. By using a series of myc-tagged polyQ–EGFP fusion constructs (21), we showed that Xpo1 interacted only with Q81–EGFP, but not with Q19–EGFP, in HEK293 cells (Fig. 3A). Similar expanded polyQ-specific interactions were also observed between Xpo1 and disease proteins, including those that cause Machado Joseph Disease [Machado-Joseph Disease (MJD); MJDtrQ78; Fig. 3B] and Huntington’s disease (HD; Htt1–85Q83; Fig. 3C). Notably, we found that Xpo1 interacted only with sodium dodecylsulfate (SDS)-soluble Q81-EGFP, but not with the SDS-insoluble ones resided in stacking gel (Supplementary Material, Fig. S2). This indicates that such protein–protein interaction is not mediated through non-specific recruitment to protein aggregates. As the interaction between Xpo1 and its export substrate is a pre-requisite for receptor-mediated protein nuclear export
of Xpo1 into protein aggregates, like the cAMP response protein. The sequestration of Xpo1 and hence mediates its nuclear export. We next addressed whether the interaction between expanded polyQ protein and Xpo1 would lead to the sequestration of Xpo1 into protein aggregates, like the cAMP response protein.

Expanded polyQ protein/Xpo1 interaction does not affect cellular Xpo1-mediated protein nuclear export

We next addressed whether the interaction between expanded polyQ protein and Xpo1 would lead to the sequestration of Xpo1 into protein aggregates, like the cAMP response protein. The sequestration of Xpo1 and hence mediates its nuclear export. We next addressed whether the interaction between expanded polyQ protein and Xpo1 would lead to the sequestration of Xpo1 into protein aggregates, like the cAMP response protein.

Exportin-1 modulates polyQ toxicity by altering nucleocytoplasmic localization of expanded polyQ proteins

In an attempt to correlate the nuclear export activity of expanded polyQ domain to polyQ toxicity, we further extended our study to in vivo transgenic disease models. The full-length MJD transgene, MJDQ84, was expressed in adult Drosophila retinal neurons using the GAL4/UAS system (Fig. 5). Neurotoxicity of this model has previously been described (24). When Xpo1 expression was knocked down by dsRNA (Supplementary Material, Fig. S4), its nuclear export substrate, MJDQ84, retained predominantly in the nucleus (Fig. 5A and B). In contrast, Xpo1 over-expression (Supplementary Material, Fig. S4) promoted MJDQ84 nuclear export and thus resulted in a cytoplasmic enrichment of MJDQ84 (Fig. 5A and B). Consistent with our in vitro binding data that only the expanded polyQ

---

**Figure 1.** Subcellular localization of EGFP–Q75 aggregates in Drosophila neuronal BG2 cells. (A) At 96 h post-induction, EGFP–Q27 localized homogeneously in BG2 cells, while EGFP–Q75 formed aggregates in both cytoplasm and nucleus. Scale bar represents 5 μm. (B) The knockdown efficiency of dsRNAs used in this study. Compared with water-treated control (−), treatment of BG2 cells with specific dsRNAs (+) caused a reduction in target gene mRNA. β-actin was used as a loading control.

**Table 1.** Gene knockdown effects of different nuclear transport receptors/adaptors on the subcellular localization of EGFP–Q75 in Drosophila neuronal BG2 cells

<table>
<thead>
<tr>
<th>Gene</th>
<th>Average no. of cells with NAs</th>
<th>Average no. of cells with CAs</th>
<th>Average no. of cells with NAs and CAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cas</td>
<td>33 ± 3</td>
<td>48 ± 2</td>
<td>23 ± 6</td>
</tr>
<tr>
<td>cdm</td>
<td>25 ± 4</td>
<td>55 ± 2</td>
<td>20 ± 4</td>
</tr>
<tr>
<td>CG10478</td>
<td>34 ± 6</td>
<td>48 ± 4</td>
<td>18 ± 2</td>
</tr>
<tr>
<td>CG10950</td>
<td>37 ± 2</td>
<td>47 ± 4</td>
<td>16 ± 7</td>
</tr>
<tr>
<td>CG32165</td>
<td>37 ± 3</td>
<td>47 ± 5</td>
<td>16 ± 6</td>
</tr>
<tr>
<td>CG8219</td>
<td>34 ± 3</td>
<td>52 ± 4</td>
<td>14 ± 1</td>
</tr>
<tr>
<td>Exportin-1</td>
<td>59 ± 1</td>
<td>30 ± 3</td>
<td>11 ± 2</td>
</tr>
<tr>
<td>Exportin-6</td>
<td>32 ± 6</td>
<td>50 ± 3</td>
<td>18 ± 3</td>
</tr>
<tr>
<td>Kap-α1</td>
<td>26 ± 3</td>
<td>56 ± 3</td>
<td>18 ± 1</td>
</tr>
<tr>
<td>Kap-α3</td>
<td>24 ± 3</td>
<td>56 ± 4</td>
<td>20 ± 5</td>
</tr>
<tr>
<td>Kary-β3</td>
<td>26 ± 4</td>
<td>54 ± 5</td>
<td>20 ± 1</td>
</tr>
<tr>
<td>msk</td>
<td>40 ± 1</td>
<td>44 ± 5</td>
<td>16 ± 6</td>
</tr>
<tr>
<td>pen</td>
<td>31 ± 2</td>
<td>50 ± 10</td>
<td>19 ± 7</td>
</tr>
<tr>
<td>Ranbp9</td>
<td>36 ± 3</td>
<td>46 ± 4</td>
<td>18 ± 5</td>
</tr>
<tr>
<td>Ranbp11</td>
<td>35 ± 2</td>
<td>47 ± 6</td>
<td>18 ± 3</td>
</tr>
<tr>
<td>Ranbp16</td>
<td>35 ± 3</td>
<td>49 ± 2</td>
<td>16 ± 2</td>
</tr>
<tr>
<td>Ranbp21</td>
<td>34 ± 3</td>
<td>46 ± 3</td>
<td>20 ± 1</td>
</tr>
<tr>
<td>trn</td>
<td>34 ± 4</td>
<td>49 ± 2</td>
<td>17 ± 6</td>
</tr>
<tr>
<td>Trn-SR</td>
<td>37 ± 7</td>
<td>47 ± 2</td>
<td>16 ± 5</td>
</tr>
</tbody>
</table>

One hundred cells were counted in each experiment, and a total of 300 cells were counted from three independent experiments (mean ± SD). CA and NA denote cytoplasmic and nuclear aggregates, respectively. ‘+’ represents no dsRNA control.

(17), we demonstrated here that the pathogenic expansion of polyQ domain renders disease protein an ability to interact with Xpo1 and hence mediates its nuclear export.
proteins interacts with Xpo1 (Fig. 3 and Supplementary Material, Fig. S2), the unexpanded control (MJDQ27) did not show such modulation of its subcellular localization upon Xpo1 knockdown (Fig. 5A). This clearly demonstrated that Xpo1 specifically modifies the subcellular localization of expanded polyQ protein. As the depletion of Xpo1 enhanced retinal degeneration while its overexpression attenuated MJDQ84 toxicity (Fig. 5C and D; 25), our data indicated that the subcellular localization of MJDQ84 is tightly linked to degeneration and that MJDQ84 exerts its toxicity predominantly in the nucleus.

The modifying effect of Xpo1 was also tested in other Drosophila models of neurodegenerative diseases, including more polyQ diseases and Parkinson’s disease. Among all the polyQ disease models investigated, including those for spinal and bulbular muscular atrophy (26), HD (27) and an artificial EGFP-Q76 model (28), the knockdown of Xpo1 expression all enhanced polyQ toxicity (Supplementary Material, Fig. S5). In contrast, the neurotoxicity caused by α-synuclein (the disease protein for Parkinson’s disease) (29) was insensitive to Xpo1 (Supplementary Material, Fig. S6). Therefore, our results support the notion that Xpo1 specifically modulates expanded polyQ-induced toxicity.

**Nuclear disease protein enhances polyQ toxicity by suppressing the cellular heat shock response**

We then investigated how nuclear accumulation of MJDQ84 caused polyQ toxicity. Heat shock response is a cellular defense mechanism to prevent misfolding and/or aggregation of disease proteins (30). The expression of expanded polyQ protein elicits heat shock response through the induction of hsp gene expression. However, we have previously reported that the continuous expression of the expanded truncated MJD protein (MJDtrQ78) in vivo would cause a reduction in hsp gene induction (31). Such biphasic hsp gene expression
profile has also been reported in different polyQ disease models (31–33). As reported earlier (31), we also detected an induction of \textit{hsp70} mRNA expression in this full-length MJDQ84 transgenic fly model (Fig. 6A, lane 8). Similar induction of other \textit{hsps}, including \textit{hsp22} and \textit{hsp40}, was also observed (data not shown). Nonetheless, such induction was diminished in MJDQ84 flies co-expressing \textit{Xpo1} dsRNA (Fig. 6A, lane 9). We further showed that the general \textit{hsp} gene induction machinery in MJDQ84/ds\_\textit{Xpo1} double-transgenic flies was compromised as they failed to respond to elevated temperature, a universal heat shock stimulus (Fig. 6A, lane 9). Interestingly, the expression of MJDQ84 protein alone did not cause any defect in general heat shock response (Fig. 6A, lane 8), so as when \textit{Xpo1} expression was knocked down alone (Fig. 6A, lane 3) or in MJDQ27/ds\_\textit{Xpo1} double-transgenic flies (Fig. 6A, lane 6). The above observations clearly indicated that the absence of \textit{hsp70} induction in the MJDQ84/ds\_\textit{Xpo1} double-transgenic flies (Fig. 6A, lane 9) was not simply a consequence of \textit{Xpo1} knockdown, but an effect in association with the expression of MJDQ84. We further demonstrated that the overexpression of \textit{Xpo1} in MJDQ84 flies could robustly induce (Fig. 6, lane 10) and prolong (Supplementary Material, Fig. S7) \textit{hsp70} expression.

As \textit{Hsp70} has been reported to play neuroprotective roles in polyQ degeneration (30), our findings reinforced the idea that strategies that can maintain \textit{hsp} gene induction are beneficial to polyQ degeneration. The decline of \textit{Xpo1} protein level with age explains the progressive nature of polyQ disease

Transcriptional dysregulation is one of the pathogenic hallmarks of polyQ diseases (1). We found that the enhancing effect of \textit{Xpo1} knockdown on expanded polyQ-induced degenerative phenotype (Fig. 5C and D) was accompanied by a reduction in \textit{hsp} gene induction (Fig. 6). The late-onset and progressive nature of polyQ diseases prompted us to determine the temporal expression level of \textit{Xpo1} in an organism. Interestingly, we observed a temporal decline of the \textit{Xpo1} protein levels in both the R6/2 HD transgenic mice (37,38) (Fig. 7A and B) and wild-type mice (Supplementary Material, Fig. S9). This clearly showed a gradual reduction in the \textit{Xpo1} protein levels with time. In relation to this, we also detected a concomitant age-dependent accumulation of expanded Htt protein in the nuclear fraction isolated from symptomatic R6/2 mice (Fig. 7C). Taken together, our R6/2 biochemical analyses (Fig. 7) are in good agreement with the \textit{Xpo1} knockdown data that observed in the fly studies (Fig. 5). This indicated that the developmental decline of the \textit{Xpo1} protein...
levels contributes to the progressive buildup of expanded polyQ protein in the nucleus and hence promotes toxicity.

**DISCUSSION**

The nucleocytoplasmic localization of expanded polyQ proteins plays a pivotal role in the degenerative process of polyQ diseases (39). Although nuclear transport signals have been identified in non-polyQ regions of different disease proteins (3–5,16,40–47), proteolytic cleavage is commonly observed and generates truncated polyQ domain-containing disease proteins that lack these signals (48). Therefore, the polyQ domain itself is believed to play a determining role in the subcellular localization of disease proteins. In view of this, we used an EGFP–polyQ reporter to investigate the nuclear transport property of expanded polyQ domain. From our knockdown study carried out in BG2 cells, we identified several nuclear transport receptors/adaptors whose depletion caused altered subcellular localization of expanded polyQ protein (Fig. 1 and Table 1). Pathogenic expansion of polyQ domain has previously been shown to dictate nuclear

*Figure 4.* The protein nuclear export machinery of Xpo1 remains functional in expanded polyQ protein-expressing cells. (A) HEK293 cells transfected with Q19/Q81–EGFP were stained with anti-Xpo1 antibody. Both Q19– and Q81–EGFP proteins were found to be present in both nucleus and cytoplasm. Diffuse Xpo1 staining signal was detected mainly in the nucleus in both Q19– and Q81–EGFP-expressing cells. The Q81–EGFP protein formed protein aggregates in the nucleus, but Xpo1 was not recruited to the aggregates. Scale bar represents 20 μm. (B) Transfected HEK293 cells were stained with anti-survivin antibody. Survivin localized predominantly to the cytoplasm in both Q19– and Q81–EGFP-expressing cells. Scale bar represents 20 μm. (C) Total HEK293 cell lysates were harvested and subjected to size exclusion chromatography. High-molecular-weight complexes containing Xpo1 (fractions 5–10) were observed in both Q19– and Q81–EGFP lysates, indicating that the interaction between Xpo1 and Q81-EGFP does not disrupt Xpo1 protein complex formation.
localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious. In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro (Figs 1 and 2) and in vivo (Fig. 5A and B) data showed that the knockdown of Xpo1 expression leads to nuclear accumulation of expanded polyQ protein but exerts no modulatory effect on the unexpanded protein. Together with the demonstrated interaction between expanded polyQ domain and Xpo1 (Fig. 3A and Supplementary Material, Fig. S2), we believe that the pathogenic expansion of polyQ domain directs the disease protein to adopt an aberrant conformation that is able to be recognized by Xpo1. As Xpo1 interacts only with SDS-soluble Q81–EGFP (Supplementary Material, Fig. S2) and is not sequestered to polyQ protein aggregates (Fig. 4A), such interaction per se does not impose any adverse effect to the cellular Xpo1-mediated nuclear export machinery (Fig. 4B and C).

Being an Xpo1 export substrate (Fig. 2), majority of cells we analyzed showed diffuse cytoplasmic Q81–EGFP localization of a cytoplasmic protein (14), yet the detailed import machinery remained mysterious.

In this study, we reported, for the first time, that expanded polyQ domain possesses NES activity. Consistent with this view, it has previously been reported that the disease protein for dentatorubral and pallidoluysian atrophy, Atrophin-1, when carrying an expanded polyQ domain was found to localize more frequently to the cytoplasm when compared with its unexpanded form (5). Exportin-1 is the nuclear export receptor for the classical leucine-rich NESs (17). LMB covalently modifies the Cys-529 residue in the NES-binding pocket of Xpo1 which subsequently causes inactivation of Xpo1’s nuclear export activity (49). Although expanded polyQ domain shows no resemblance to this group of NES, our LMB treatment and knockdown results clearly demonstrate that Xpo1 mediates its nuclear export (Figs 1–3). Both our in vitro
localization (Table 2). However, we also found cells that only showed nuclear Q81–EGFP signals (Fig. 4A and Table 2). We believe that these signals would be contributed by the SDS-insoluble Q81–EGFP protein species resided in the nucleus. Since we demonstrated that SDS-insoluble polyQ protein is incapable of interacting with Xpo1 (Supplementary Material, Fig. S2), protein of such property would not be able to be exported out of the nucleus and thus become

Figure 6. The nuclear MJDQ84 protein causes toxicity by suppressing cellular heat shock response. (A) Heat shock response in polyQ flies expressing different levels of Xpo1. Expression of full-length MJD unexpanded polyQ protein MJDQ27 (lane 5) did not cause heat shock gene induction, as hsp70 expression in MJDQ27 flies remained at the non-transgenic control level (lane 2). In contrast, expression of expanded MJDQ84 protein in flies induced hsp70 expression (lane 8). Knockdown of Xpo1 expression (Supplementary Material, Fig. S4) in MJDQ84 flies (lane 9) impaired hsp70 induction. In contrast, overexpression of Xpo1 (Supplementary Material, Fig. S4) promoted hsp70 induction (lane 10). Modulation of Xpo1 expression levels in the presence (lanes 6 and 7) or absence (lanes 3 and 4) of MJDQ27 expression in flies did not alter hsp70 expression level. The hsp70 level remained unchanged in α-synuclein flies expressing either normal endogenous (lane 11), reduced (lane 12) or overexpressed (lane 13) levels of Xpo1. Compared with the untreated (no heat shock) control (lane 1), heat shock treatment led to robust hsp70 induction in all samples except for flies co-expressing MJDQ84 and Xpo1 dsRNA (lane 9). β-actin was used as a loading control. The experiment has been repeated for three times. ‘−’ denotes no transgene expression control. (B) Expanded polyQ protein MJDQ84 interacted with the hsp70 promoter in vivo (n = 3). (C) When compared with flies expressing MJDQ84 alone, MJDQ84 flies co-expressing Xpo1 dsRNA and Xpo1 transgene, respectively, promoted and reduced MJDQ84/hsp70 promoter protein–DNA interaction (n = 3). (D) Expression of human hsp70, HSPA1L, via the GAL4/UAS transgenic overexpression system rescued degeneration caused by MJDQ84/Xpo1 dsRNA coexpression. (E) Quantification of (D) (*P < 0.001, n = 3). The flies were of genotypes w; gmr-GAL4/+, w; gmr-GAL4 UAS-myc-MJDQ27/+; w; gmr-GAL4 UAS-myc-MJDQ27/UAS-Xpo1-dsRNA, w; gmr-GAL4 UAS-myc-MJDQ27/Xpo1EP-E128-1A, w; gmr-GAL4/+, UAS-myc-MJDQ84/+, w; gmr-GAL4/UAS-Xpo1 dsRNA, UAS-myc-MJDQ84/+; w; gmr-GAL4/Xpo1EP-E128-1A, UAS-myc-MJDQ84/+; w; gmr-GAL4/UAS-Xpo1-dsRNA, UAS-a-synuclein+/+, w; gmr-GAL4/UAS-Xpo1 dsRNA, UAS-a-synuclein+/+, w; gmr-GAL4/Xpo1EP-E128-1A, UAS-a-synuclein+/+ and w; gmr-GAL4 UAS-Xpo1-dsRNA/UAS-HSPA1L; UAS-myc-MJDQ84/+.
Our data are also in good agreement with previous reports that nuclear localization of the expanded MJD protein is critical for disease manifestation (2), and transcriptional dysregulation is the pathogenic event commonly observed in MJD models in our study (Supplementary Material, Fig. S5). We demonstrated a developmental decline of Xpo1 protein levels (32,53–55). A decline in the Xpo1 levels results in decrease of Hsp70 level reported in polyQ transgenic mice (30). However, Xpo1 suppresses polyQ toxicity by promoting the nuclear export of expanded polyQ protein, a specific process that depends on the particular interaction between expanded polyQ protein and Xpo1 (Fig. 5, and Supplementary Material, Figs S5 and S6). Molecular chaperones, such as Hsp70, mitigate neurodegeneration by assisting the refolding of misfolded proteins in general (30). However, Xpo1 suppresses polyQ toxicity by promoting the nuclear export of expanded polyQ protein, a specific process that depends on the particular interaction between expanded polyQ protein and Xpo1 (Fig. 3 and Supplementary Material, Fig. S2). Such an interaction promotes the nuclear export of expanded polyQ proteins. Although nuclear toxicity of α-synuclein has been reported (36), it is speculated that the inability of Xpo1 to modulate α-synuclein-induced toxicity is attributed to a lack of receptor–substrate interaction between Xpo1 and α-synuclein.

In line with the progressive nature of polyQ degeneration, we demonstrated a developmental decline of Xpo1 protein levels in both wide-type and R6/2 HD transgenic mice (Fig. 7 and Supplementary Material, Fig. S9). Such observation is indeed in good agreement with the progressive decrease of hsp70 level reported in polyQ transgenic mice (32,53–55). A decline in the Xpo1 levels results in nuclear accumulation of expanded polyQ protein, which then disrupts hsp70 transcription through binding to its promoter (Fig. 6C), and hence leads to a reduction in the Hsp70 level. Our data obtained from the Drosophila MJDQ84/ ds_Xpo1 model (Figs 5 and 6) are also coherent with the mouse data (Fig. 7 and Supplementary Material, Fig. S9).
progressive nature of polyQ degeneration. 

Owing to the developmental decline of Xpo1 protein promoter and hence interferes with gene transcription. Expanded polyQ protein is capable of interacting with hsp on nuclear export. Owing to the developmental decline of Xpo1 protein level, expanded polyQ protein accumulates in the nucleus, interacts with gene promoter and hence causes transcriptional dysregulation.

MATERIALS AND METHODS

Molecular cloning and DNA constructs

The pcDNA3.1-Q19-EGFP-myc and pcDNA3.1-Q81-EGFP-myc constructs used were previously described in (21), and the methodology used to synthesize these constructs was described in (56). The EGFP-polyQ fragments were polymerase chain reaction (PCR) amplified from pUAST-EGFP-Q27 and pUAST-EGFP-Q76 constructs (28) and cloned into the Drosophila expression vector pMT/v5-A using Kpn1 and NorI enzymes. For the generation of pRev(1.4)-polyQ-EGFP constructs, polyQ-coding DNA fragments were amplified from pcDNA3.1-polyQ-EGFP-myc constructs and subcloned into pRev(1.4)-EGFP (18) using BamHI and AgeI enzymes. The truncated MJD fragment was subcloned from UAS-MJDtr transgenic fly cDNA templates (57) into pcDNA3.1(+) using EcoRI and Xbal enzymes. The Htt fragment was subcloned from pcDNA3FLAG-Htt1–550polyQ constructs (a kind gift of Prof. Marcy McDonald) into pCMV-Tag2B using BamHI and EcoRI enzymes.

Drosophila BG2 cell culture. The Drosophila neuronal BG2-c6 (BG2) cells were cultured in M3 medium supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin–streptomycin and 10 μg/ml insulin at 25°C. BG2 cells were co-transfected with pMT/v5-EGFP-polyQ and pH5neo using Cellfectin (Invitrogen) according to manufacturer’s protocol. Stable cell lines carrying the EGFP-polyQ transgenes were established using 2 mg/ml G418 (Calbiochem).

The DNA templates for dsRNA synthesis were PCR amplified using the 5’ T7 promoter sequence (5’-TAATACGACTCACTATAGGGAGA-3’) in combination with 3’ gene-specific primers. Primer sequences were adopted from the Drosophila RNAi Screening Center website (http://www.flyrnai.org/cgi-bin/RNAi_find_primers.pl). Double-stranded RNAs were synthesized and purified using MEGAscript T7 kit (Ambion) and NucAway Spin Column (Ambion), respectively.

The dsRNAs were introduced into BG2 cells using the bathing method (58). After 72 h of incubation, EGFP-polyQ transgene expression was induced by 1 mM CuSO4 and cells were cultured for another 96 h. Cells were fixed, stained (5 μM Hoechst) and observed on a TC SP5 confocal microscope (Leica). Cells showed cytoplasmic, nuclear and both cytoplasmic and nuclear aggregates were counted on a single-blinded approach. For every candidate gene, a total of 300 cells, captured from three independent experiments, were analyzed.

Mammalian cell culture

HEK293 cells were cultured at 37°C with 5% CO2 in high glucose Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. Transfection was performed with Lipofectamine 2000 (Invitrogen). For the Rev(1.4)-EGFP export assay, at 8 h post-transfection, transfected cells were treated with 5 μM cycloheximide and 100 nM LMB and incubated for 4 h. To knock down Xpo1 expression, 10 μM siRNA (ON-TARGETplus...
SMARTpool, Dharmacon) was used to transfect HEK293 cells. Cells were fixed and nuclei were labeled with Hoechst (5 μM), followed by microscopic observation on a BX51 fluorescence microscope (Olympus). At least 100 cells were monitored from each of the five independent transfections.

Drosophila stocks. Flies were raised on cornmeal medium supplemented with dry yeast. The fly strains used included UAS-myc-MJDQ27, UAS-myc-MJDQ84 (24); UAS-Xpo1-dsRNA (National Institute of Genetics, Japan); Xpo1 EP line E128–1A (25); UAS-HSPA1L (35), UAS-HA-Atrq112(a) (26), UAS-Htt-exon1Q93 (27), UAS-EGFPQ76-FLAG (28), UAS-a-synucleinWT (29) and gmr-GAL4 (Bloomington Drosophila Stock Center, USA). Heat shock treatment of transgenic flies was performed as previously described (31).

**Pseudopupil assay**

Adult fly eyes were examined as previously described (28). At least 100 ommatidia from 5 to 10 flies were used to calculate the average number of rhabdomeres per ommatidium in each of the three independent crosses.

**Nucleocytoplasmic fractionation of protein samples**

Frozen whole brain samples isolated from R6/2 HD transgenic mice of appropriate ages were purchased from The Jackson Laboratory. To obtain total protein lysates, thawed mouse brains or adult transgenic fly heads were homogenized in ice-cold lysis buffer (20 mM Tris–HCl, 2% SDS, 50 mM dithiothreitol) and cleared by centrifugation at 16,000g for 15 min at 4°C. To prepare cytoplasmic and nuclear protein fractions, thawed brains from R6/2 mice or transgenic fly heads were homogenized in fractionation buffer (10 mM Tris–HCl, 10 mM NaCl, 3 mM MgCl₂, 0.5% NP-40) as previously described (15). Formic acid treatment of fractionated samples was performed as previously described (59) with the protein pellets resuspended in SDS sample buffer.

**Western blotting**

The MJ2Q27/Q84 proteins isolated from adult fly heads were detected by anti-myc antibody 9B11 (1:2500, Cell Signaling Technology). The same blots were probed with anti-β-tubulin E7 (1:10,000, Developmental Studies Hybridoma Bank) and anti-histone H3 (1:10,000, Abcam) antibodies to determine the purities of fractions and as loading controls. Expanded Huntington protein was detected by antibodies to determine the purities of fractions and as loading controls. Immunoprecipitates were used as negative control. Immunoprecipitates were analyzed by sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS–PAGE) and western blotting. Anti-Xpo1 antibody (1:1000, Calbiochem) was used to detect Xpo1 protein and the same blot was re-probed with anti-myc 71D10 (1:1000, Cell Signaling Technology) or anti-FLAG M2 (1:2500, Sigma) antibodies to show the expression of myc-tagged polyQ-EGFP or FLAG-tagged MJD and Htt proteins. Secondary antibodies used were affinity-purified goat anti-rabbit and goat anti-mouse IgG peroxidase conjugate (1:2500, Cell Signaling Technology).

**Chromatin immunoprecipitation**

The ChIP assay was performed on MJ2Q27 and MJ2Q84 transgenic fly lysates as previously described (61). The chromatin solutions were incubated with anti-myc 9B11 (1:250, Cell Signaling Technology) and protein A agarose overnight at 4°C. After washing, immunoprecipitates were eluted and DNA was precipitated. The pelleted DNA was re-suspended in H₂O and used as template for hsp70 promoter PCR amplification using primers as described (62).

**Size exclusion chromatography**

HEK293 cells expressing either Q19– or Q81–EGFP were harvested in Xpo1-binding buffer. Size exclusion chromatography was performed using the HiPrep 26/60 Sephacryl S-300 column operated on an AKTAprime Plus System (GE Healthcare). Ferritin (440 kDa), aldolase (158 kDa) and albumin (67 kDa) were used as molecular size standards. Fractions were subjected to SDS–PAGE and western blotting using anti-Xpo1 antibody (1:1000, Calbiochem).

**Confocal microscopy**

Transfected HEK293 cells were fixed and stained with anti-Xpo1 (clone 17, 1:1000, BD Transduction Laboratories) and anti-survivin (1:1000, R&D Systems) antibodies, followed by tetramethylrhodamine isothiocyanate-conjugated secondary antibodies (1:250, Invitrogen). GFP fluorescence signal was used to detect Q19– and Q81–EGFP protein. After labeling the nuclei with TO-PRO-3 (1:400, Invitrogen), cell images were captured by the TC SP5 confocal system (Leica). Consistent results were obtained from three independent sets of transfection.

**Reverse transcription–PCR (RT–PCR)**

Total RNA extraction, conditions for RT–PCR, and the primers used in the amplification of β-actin and hsp70 were essentially the same as previously described (31).

**Statistical analyses**

Protein bands and PCR amplicons were quantified by the Image J software (version 1.32; Research Services Branch, National Institute of Mental Health). The Kruskal–Wallis one-way ANOVA on ranks followed by Dunn post-test was performed to determine the difference in the Rev(1.4)-EGFP export assay (Fig. 2B and D). The Mann–Whitney rank sum test was performed to determine mean differences when comparing results for the nucleocytoplasmic ratio of polyQ...
proteins (Fig. 5B), pseudopupil assays (Figs 5D, 6E, and Supplementary Material, Figs S6 and S10), and temporal analysis of the Xpo1 level (Fig. 7 and Supplementary Material, Fig. S9) between groups. Two-tailed, unpaired Student’s t-test was performed to analyze the dsRNA data obtained from BG2 cells (Table 1). A P-value of < 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We thank Dr Cahir O’Kane, Dr Terrence Lau, Dr Sheng Zhang, Dr Bernard Mathey-Prevot, current and past members of the Laboratory of Drosophila Research for helpful discussion; Dr Nancy Bonini for fly stocks; Dr Beric Henderson for pRev(1.4)-EGFP constructs, Dr Marcy McDonald for Huntingtin constructs and Dr Tatsushi Toda for polyQ-EGFP-myc constructs.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by CERG (CUHK4314/03M, CUHK4413/04M) and GRF (460908) grants from the Research Grants Council of Hong Kong, and the Hong Kong Spinocerebellar Ataxia Association.

REFERENCES


